ABSTRACT
Importance: There are no approved drug treatments for autosomal dominant retinitis pigmentosa, a relentlessly progressive cause of adult and childhood blindness. Objectives: To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa. Design, Setting, and Participants: Multicenter, phase 2, prospective, interventional, placebo-controlled, double-masked randomized clinical trial. The study took place in 6 US academic retinal degeneration centers. Individuals with genetically characterized autosomal dominant retinitis pigmentosa were randomly assigned to receive treatment or placebo for 12 months. Analyses were intention-to-treat. Interventions: Oral VPA 500 mg to 1000 mg daily for 12 months or placebo. Main Outcomes and Measures: The primary outcome measure was determined prior to study initiation as the change in visual field area (assessed by the III4e isopter, semiautomated kinetic perimetry) between baseline and month 12. Results: The mean (SD) age of the 90 participants was 50.4 (11.6) years. Forty-four (48.9%) were women, 87 (96.7%) were white, and 79 (87.8%) were non-Hispanic. Seventy-nine participants (87.8%) completed the study (42 [95.5%] received placebo and 37 [80.4%] received VPA). Forty-two (46.7%) had a rhodopsin mutation. Most adverse events were mild, although 7 serious adverse events unrelated to VPA were reported. The difference between the VPA and placebo arms for mean change in the primary outcome was -150.43 degree2 (95% CI, -290.5 to -10.03; P = .035). Conclusions and Relevance: This negative value indicates that the VPA arm had worse outcomes than the placebo group. This study brings to light the key methodological considerations that should be applied to the rigorous evaluation of treatments for these conditions. This study does not provide support for the use of VPA in the treatment of autosomal dominant retinitis pigmentosa. Trial Registration: ClinicalTrials.gov Identifier: NCT01233609.
Subject(s)
Anticonvulsants/therapeutic use , Retinitis Pigmentosa/drug therapy , Valproic Acid/therapeutic use , Vision Disorders/drug therapy , Administration, Oral , Adult , Aged , Anticonvulsants/administration & dosage , Double-Blind Method , Electroretinography , Female , Humans , Male , Middle Aged , Mutation , Prospective Studies , Retina/physiopathology , Retinitis Pigmentosa/genetics , Retinitis Pigmentosa/physiopathology , Rhodopsin/genetics , Valproic Acid/administration & dosage , Vision Disorders/physiopathology , Visual Acuity/physiology , Visual Field Tests , Visual Fields/physiologyABSTRACT
BACKGROUND AND OBJECTIVE: The objective of this study was to compare visual acuity outcomes between the following procedures used to treat submacular hemorrhages: pneumatic displacement followed by intravitreal tissue plasminogen activator (tPA) if needed (pneumatic ± tPA) and pars plana vitrectomy (PPV) with subretinal tPA (PPV + tPA). PATIENTS AND METHODS: This is a retrospective chart review of submacular hemorrhages treated with either pneumatic ± tPA or PPV + tPA. RESULTS: Eighteen patients had pneumatic ± tPA, and 14 patients had PPV + tPA. The percentage of patients achieving three lines or greater of vision improvement 1 year postoperatively was 46% and 18% in these groups, respectively (P = .194). CONCLUSION: The difference in visual acuity was not statistically significant; however, the lack of a statistical difference is important as pneumatic ± tPA is a less-invasive, less costly procedure that can be done in a clinical setting. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:26-32.].
Subject(s)
Retinal Hemorrhage/drug therapy , Tissue Plasminogen Activator/administration & dosage , Visual Acuity , Aged , Female , Follow-Up Studies , Humans , Injections , Intravitreal Injections , Macula Lutea/pathology , Male , Retina , Retinal Hemorrhage/diagnosis , Retrospective Studies , Tomography, Optical Coherence , Treatment OutcomeSubject(s)
Immunosuppressive Agents/administration & dosage , Macular Edema/drug therapy , Retinal Diseases/drug therapy , Retinitis Pigmentosa/complications , Retinitis Pigmentosa/drug therapy , Triamcinolone Acetonide/administration & dosage , Vitreous Body/drug effects , Adrenal Cortex Hormones/pharmacology , Glucocorticoids/administration & dosage , Humans , Injections , Retrospective Studies , Time Factors , Treatment OutcomeABSTRACT
This is the first reported case of delayed-onset postcataract endophthalmitis caused by Mycobacterium goodii, confirmed by multiple cultures. The patient had uneventful cataract removal by phacoemulsification with implantation of a posterior chamber intraocular lens (IOL). One month later, he developed redness, pain, a hypopyon, and a decrease in visual acuity to finger counting in the affected eye. A vitreous biopsy was performed for suspected endophthalmitis; culture results showed rapidly growing bacteria identified by DNA sequencing as Mycobacterium goodii. The eye ultimately required IOL explantation but had a good final outcome with 20/40 uncorrected vision. Mycobacterium goodii is a rapidly growing Mycobacterium with isolates more commonly occurring in cellulitis, osteomyelitis, and respiratory disease. Single-drug antibiotic therapy for nonocular disease is often sufficient if the correct antimicrobial agent is used. The newer fluoroquinolones are promising against rapidly growing Mycobacterium.